Crossmark

Antisecretory Factor 16 (AF16): A Promising Avenue for the Treatment of Traumatic Brain Injury—An In Vitro Model Approach

Crossref DOI link: https://doi.org/10.1007/s12031-024-02268-6

Published Online: 2024-11-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Vahrmeijer, Nicola https://orcid.org/0000-0002-6856-6014
Kriel, Jurgen https://orcid.org/0000-0001-7558-7916
Harrington, Bradley M. https://orcid.org/0009-0009-9242-7119
van Staden, Anton Du Preez https://orcid.org/0000-0003-0596-8849
Vlok, Adriaan Johannes https://orcid.org/0000-0002-3202-2867
Engelbrecht, Lize https://orcid.org/0000-0002-4518-7011
Du Toit, Andre https://orcid.org/0000-0002-3936-6013
Loos, Ben https://orcid.org/0000-0002-5517-373X
Funding

Funding for this research was provided by:

Stellenbosch University
License Information

Text and Data Mining valid from 2024-11-07

Version of Record valid from 2024-11-07
More Information

Article History

Received: 18 April 2024

Accepted: 16 September 2024

First Online: 7 November 2024

Declarations

:

: NA.

: NA.

: The authors declare no competing interests.